SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The revenue zoomed 16.46% to Rs. 9108.70 millions for the quarter ended March 2024 as compared to Rs. 7821.60 millions during the corresponding quarter last year.A good growth in profit of 46.85% reported to Rs. 1930.80  millions over Rs. 1314.80 millions of corresponding previous quarter.OP of the company witnessed a marginal growth to 2851.80 millions from 1947.30 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 9108.70 7821.60 16.46 34072.50 32163.40 5.94 34072.50 32163.40 5.94
Other Income 298.70 279.70 6.79 1234.80 1015.20 21.63 1234.80 1015.20 21.63
PBIDT 2851.80 1947.30 46.45 10241.30 9009.30 13.67 10241.30 9009.30 13.67
Interest 7.70 6.50 18.46 18.00 18.10 -0.55 18.00 18.10 -0.55
PBDT 2868.10 2044.80 40.26 8787.20 8981.50 -2.16 8787.20 8981.50 -2.16
Depreciation 181.00 171.80 5.36 696.80 657.70 5.94 696.80 657.70 5.94
PBT 2687.10 1873.00 43.47 8090.40 8323.80 -2.80 8090.40 8323.80 -2.80
TAX 756.30 558.20 35.49 2243.50 2276.80 -1.46 2243.50 2276.80 -1.46
Deferred Tax 144.70 -7.60 -2003.95 -113.60 -183.70 -38.16 -113.60 -183.70 -38.16
PAT 1930.80 1314.80 46.85 5846.90 6047.00 -3.31 5846.90 6047.00 -3.31
Equity 1694.10 1694.10 0.00 1694.10 1694.10 0.00 1694.10 1694.10 0.00
PBIDTM(%) 31.31 24.90 25.76 30.06 28.01 7.31 30.06 28.01 7.31

Glaxosmithkline Phar Share Price

2432.10 -19.70 (-0.80%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×